| Drug Name | (Lucentis®(Ranibizumab |
|---|---|
| Drug Class |
Immunosuppressant
|
| Risk minimization type |
patient guide
|
| Specialty (Theraputic area) |
Ophthalmology
|
| Risk |
Safety information about risk of Infections Endophthalmitis.,Traumatic Cataract., Intraocular inflammation and Rhegmatogenous retinal detachment or retinal tear. |
| patient guide |
|
| Health care provider guide |
|
| other |
Patient Guide for the treatment for the treatment of visual impairment due to diabetic macular edema (DME).
Patient Guide for the treatment of visual impairment due to macular edema secondary to retinal vein occlusion (branch RVO or cen
Patient Guide for the treatment of neovascular (wet) age-related macular degeneration (AMD). |